Literature DB >> 22691495

Loss of functional GABA(A) receptors in the Alzheimer diseased brain.

Agenor Limon1, Jorge Mauricio Reyes-Ruiz, Ricardo Miledi.   

Abstract

The cholinergic and glutamatergic neurotransmission systems are known to be severely disrupted in Alzheimer's disease (AD). GABAergic neurotransmission, in contrast, is generally thought to be well preserved. Evidence from animal models and human postmortem tissue suggest GABAergic remodeling in the AD brain. Nevertheless, there is no information on changes, if any, in the electrophysiological properties of human native GABA receptors as a consequence of AD. To gain such information, we have microtransplanted cell membranes, isolated from temporal cortices of control and AD brains, into Xenopus oocytes, and recorded the electrophysiological activity of the transplanted GABA receptors. We found an age-dependent reduction of GABA currents in the AD brain. This reduction was larger when the AD membranes were obtained from younger subjects. We also found that GABA currents from AD brains have a faster rate of desensitization than those from non-AD brains. Furthermore, GABA receptors from AD brains were slightly, but significantly, less sensitive to GABA than receptors from non-AD brains. The reduction of GABA currents in AD was associated with reductions of mRNA and protein of the principal GABA receptor subunits normally present in the temporal cortex. Pairwise analysis of the transcripts within control and AD groups and analyses of the proportion of GABA receptor subunits revealed down-regulation of α1 and γ2 subunits in AD. In contrast, the proportions of α2, β1, and γ1 transcripts were up-regulated in the AD brains. Our data support a functional remodeling of GABAergic neurotransmission in the human AD brain.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22691495      PMCID: PMC3382476          DOI: 10.1073/pnas.1204606109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

Review 1.  Neuron numbers and dendritic extent in normal aging and Alzheimer's disease.

Authors:  P D Coleman; D G Flood
Journal:  Neurobiol Aging       Date:  1987 Nov-Dec       Impact factor: 4.673

2.  Benzodiazepine use and risk of dementia: evidence from the Caerphilly Prospective Study (CaPS).

Authors:  John Gallacher; Peter Elwood; Janet Pickering; Antony Bayer; Mark Fish; Yoav Ben-Shlomo
Journal:  J Epidemiol Community Health       Date:  2011-10-27       Impact factor: 3.710

3.  A transient calcium-dependent chloride current in the immature Xenopus oocyte.

Authors:  M E Barish
Journal:  J Physiol       Date:  1983-09       Impact factor: 5.182

4.  AMPA-selective glutamate receptor subtype immunoreactivity in the entorhinal cortex of non-demented elderly and patients with Alzheimer's disease.

Authors:  D M Armstrong; M D Ikonomovic; R Sheffield; R J Wenthold
Journal:  Brain Res       Date:  1994-03-14       Impact factor: 3.252

Review 5.  Gephyrin: where do we stand, where do we go?

Authors:  Jean-Marc Fritschy; Robert J Harvey; Günter Schwarz
Journal:  Trends Neurosci       Date:  2008-04-09       Impact factor: 13.837

6.  GABAA/benzodiazepine receptors in acutely isolated hippocampal astrocytes.

Authors:  D D Fraser; S Duffy; K J Angelides; J L Perez-Velazquez; H Kettenmann; B A MacVicar
Journal:  J Neurosci       Date:  1995-04       Impact factor: 6.167

7.  Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing.

Authors:  Maryline Marcade; Jérôme Bourdin; Nadia Loiseau; Hélène Peillon; Aurélie Rayer; Dominique Drouin; Fabien Schweighoffer; Laurent Désiré
Journal:  J Neurochem       Date:  2008-07-01       Impact factor: 5.372

8.  Phosphatase inhibitors remove the run-down of gamma-aminobutyric acid type A receptors in the human epileptic brain.

Authors:  E Palma; D A Ragozzino; S Di Angelantonio; G Spinelli; F Trettel; A Martinez-Torres; G Torchia; A Arcella; G Di Gennaro; P P Quarato; V Esposito; G Cantore; R Miledi; F Eusebi
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-24       Impact factor: 11.205

9.  Early-onset Alzheimer's disease is associated with greater pathologic burden.

Authors:  Gad A Marshall; Lynn A Fairbanks; Sibel Tekin; Harry V Vinters; Jeffrey L Cummings
Journal:  J Geriatr Psychiatry Neurol       Date:  2007-03       Impact factor: 2.680

10.  Statistical analysis of real-time PCR data.

Authors:  Joshua S Yuan; Ann Reed; Feng Chen; C Neal Stewart
Journal:  BMC Bioinformatics       Date:  2006-02-22       Impact factor: 3.169

View more
  87 in total

Review 1.  Metabolic Alterations Associated to Brain Dysfunction in Diabetes.

Authors:  João M N Duarte
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

2.  Abnormal gephyrin immunoreactivity associated with Alzheimer disease pathologic changes.

Authors:  Chadwick M Hales; Howard Rees; Nicholas T Seyfried; Eric B Dammer; Duc M Duong; Marla Gearing; Thomas J Montine; Juan C Troncoso; Madhav Thambisetty; Allan I Levey; James J Lah; Thomas S Wingo
Journal:  J Neuropathol Exp Neurol       Date:  2013-11       Impact factor: 3.685

Review 3.  The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.

Authors:  Harald Hampel; M-Marsel Mesulam; A Claudio Cuello; Martin R Farlow; Ezio Giacobini; George T Grossberg; Ara S Khachaturian; Andrea Vergallo; Enrica Cavedo; Peter J Snyder; Zaven S Khachaturian
Journal:  Brain       Date:  2018-07-01       Impact factor: 13.501

4.  A Novel 1,4-Dihydropyridine Derivative Improves Spatial Learning and Memory and Modifies Brain Protein Expression in Wild Type and Transgenic APPSweDI Mice.

Authors:  Baiba Jansone; Inga Kadish; Thomas van Groen; Ulrika Beitnere; Doyle Ray Moore; Aiva Plotniece; Karlis Pajuste; Vija Klusa
Journal:  PLoS One       Date:  2015-06-04       Impact factor: 3.240

5.  Hippocampal Mossy Fibers Synapses in CA3 Pyramidal Cells Are Altered at an Early Stage in a Mouse Model of Alzheimer's Disease.

Authors:  Silvia Viana da Silva; Pei Zhang; Matthias Georg Haberl; Virginie Labrousse; Noëlle Grosjean; Christophe Blanchet; Andreas Frick; Christophe Mulle
Journal:  J Neurosci       Date:  2019-03-18       Impact factor: 6.167

6.  Clarithromycin increases neuronal excitability in CA3 pyramidal neurons through a reduction in GABAergic signaling.

Authors:  Edyta K Bichler; Courtney C Elder; Paul S García
Journal:  J Neurophysiol       Date:  2016-10-12       Impact factor: 2.714

7.  Genetic Influences on Plasma Homocysteine Levels in African Americans and Yoruba Nigerians.

Authors:  Sungeun Kim; Kwangsik Nho; Vijay K Ramanan; Dongbing Lai; Tatiana M Foroud; Katie Lane; Jill R Murrell; Sujuan Gao; Kathleen S Hall; Frederick W Unverzagt; Olusegun Baiyewu; Adesola Ogunniyi; Oye Gureje; Mitchel A Kling; P Murali Doraiswamy; Rima Kaddurah-Daouk; Hugh C Hendrie; Andrew J Saykin
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

8.  Novel analogues of chlormethiazole are neuroprotective in four cellular models of neurodegeneration by a mechanism with variable dependence on GABA(A) receptor potentiation.

Authors:  Lawren Vandevrede; Ehsan Tavassoli; Jia Luo; Zhihui Qin; Lan Yue; David R Pepperberg; Gregory R Thatcher
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 9.  Gephyrin: a key regulatory protein of inhibitory synapses and beyond.

Authors:  Femke L Groeneweg; Christa Trattnig; Jochen Kuhse; Ralph A Nawrotzki; Joachim Kirsch
Journal:  Histochem Cell Biol       Date:  2018-09-27       Impact factor: 4.304

10.  Memory-enhancing and brain protein expression-stimulating effects of novel calcium antagonist in Alzheimer's disease transgenic female mice.

Authors:  Baiba Jansone; Inga Kadish; Thomas van Groen; Ulrika Beitnere; Aiva Plotniece; Karlis Pajuste; Vija Klusa
Journal:  Pharmacol Res       Date:  2016-06-21       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.